Antibody formulations and methods
AssigneeOnclave Therapeutics
InventorsPATRICK GARIDEL, Isaac Craig Henderson, Pamela Klein
Life of this patent
Estimating the term…
Abstract
Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.
Claims79
A pharmaceutical formulation comprising:
- (a) a chimeric or humanized version of antibody 2A4 (ATCC Accession Number PTA-9662) or of antibody 7D8 (ATCC Accession Number PTA-9468), or fragment thereof, that specifically competes for binding to antigen with 2A4 or 7D8, wherein the antibody is present at a concentration within the range from about 1 mg/mL to about 100 mg/mL;
- (b) histidine buffer present at a concentration within the range from about 20 mM to about 30 mM;
- (c) trehalose present at a concentration within the range from about 210 mM to about 250 mM;
- and
- (d) polysorbate 20 present at a concentration within the range from about 0.005% to about 0.05% by weight;
- wherein the formulation is characterized by a pH within the range from about 6 to about 7.
A pharmaceutical formulation comprising:
- (a) an antibody comprising a light chain comprising an amino acid sequence set forth as SEQ ID NO:
- 13 and a heavy chain comprising an amino acid sequence set forth as any one of SEQ ID NOs:
- 14-16, and which is present at a concentration of about 10 mg/mL;
- (b) a histidine buffer present at a concentration of about 25 mM;
- (c) trehalose present at a concentration of about 230 mM;
- (d) polysorbate 20 present at a concentration of about 0.2 g/L;
- and
- (e) a pH of about 6.5.
A pharmaceutical formulation comprising:
- (a) an antibody, which is antibody 2A4 (ATCC Accession Number PTA-9662), antibody 7D8 (ATCC Accession Number PTA-9468), or a chimeric or humanized version of antibody 2A4 or of antibody 7D8, or fragment thereof, that specifically competes for binding to antigen with 2A4 or 7D8, wherein the antibody is present at a concentration within the range from about 50 mg/mL to about 100 mg/mL;
- (b) a buffer;
- (c) a non-reducing sugar;
- and
- (d) a non-ionic surfactant.
A lyophilized formulation of an antibody, comprising
- (a) a humanized version of antibody 2A4 (ATCC Accession Number PTA-9662) or antibody 7D8 (ATCC Accession Number PTA-9468) or antigen binding fragment thereof;
- (b) histidine;
- (c) trehalose;
- and
- (d) polysorbate 20.
34-36. (canceled)
A nucleic acid comprising a nucleotide sequence encoding any one of SEQ ID NOs:
- 13, 14-16, 19, 20, 22 or 23.
38-40. (canceled)
42-44. (canceled)
(canceled)
The host cell of claim 38 having stably incorporated into its genome a nucleic acid comprising the nucleotide sequence encoding SEQ ID NO:
- 19 and a nucleic acid comprising the nucleotide sequence encoding SEQ ID NO:
- 22.
The host cell of claim 38 having stably incorporated into its genome a nucleic acid comprising the nucleotide sequence encoding SEQ ID NO:
- 20 and a nucleic acid comprising the nucleotide sequence encoding SEQ ID NO:
- 23.
(canceled)
(canceled)
56-57. (canceled)
(canceled)
A method of therapeutically or prophylactically treating a human patient having or at risk for having light chain (AL) amyloidosis characterized by the presence of amyloid fibrils, deposits or prefibrillar aggregates, comprising administering to the patient an effective dosage of a pharmaceutical formulation comprising:
- (a) an antibody comprising a light chain comprising an amino acid sequence set forth as SEQ ID NO:
- 13 and a heavy chain comprising an amino acid sequence set forth as any one of SEQ ID NOs:
- 14-16, and which is present at a concentration of about 10 mg/mL;
- (b) a histidine buffer present at a concentration of about 25 mM;
- (c) trehalose present at a concentration of about 230 mM;
- (d) polysorbate 20 present at a concentration of about 0.2 g/L;
- and
- (e) a pH of about 6.5.
A pharmaceutical product, comprising:
- (a) a vial comprising about 100 mg antibody in powder form;
- (b) instructions for reconstitution of the antibody;
- and
- (c) instructions for preparing the reconstituted antibody for infusion, wherein:
- (i) the antibody comprises a light chain comprising an amino acid sequence set forth as SEQ ID NO:
- 13 and a heavy chain comprising an amino acid sequence set forth as any one of SEQ ID NOs:
- 14-16;
- and
- (ii) the reconstitution instructions require reconstitution with water for injection to an extractable volume of 10 mL.
Dependencies are inferred from the claim text.